1.Dong ZR, Sun D, Yang YF, Zhou W, Wu R, Wang XW, Shi K, Yan YC, Yan LJ, Yao CY, Chen ZQ, Zhi XT,Li T. TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. Hepatology2020; 72:923-939(Corresponding author, SCI, IF: 17.425)
2.Guo X, Tan S, Wang T, Sun R, Li S, Tian P, Li M, Wang Y, Zhang Y, Yan Y, Dong Z, Yan L, Yue X, Wu Z, Li C, Yamagata K, Gao L, Ma C,Li T, Liang X. NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity. Hepatology. 2022 Jul 11. doi: 10.1002/hep.32658. (co-Corresponding author, SCI, IF: 17.425).
3.Dong ZR, Ke AW,Li T, Cai JB, Yang YF, Zhou W, Shi GM, Fan J. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. Mol Cancer2021;20(1):75. (Co-first author, SCI, IF: 41.444)
4.Hong JG, Yan LJ, Li X, Yao SY, Su P, Li HC, Ding ZN, Wang DX, Dong ZR, Li T. Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol 2022; 28(6): 689-692(Corresponding author, SCI, IF: 5.347)
5.Liu H, Yang XL, Dong ZR, Chen ZQ, Hong JG, Wang DX, Li T. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022 Jun 20. doi: 10.1111/jgh.15915. Epub ahead of print. (Corresponding author, SCI, IF: 4.369).
6.Ding ZN, Meng GX, Xue JS, Yan LJ, Liu H, Yan YC, Chen ZQ, Hong JG, Wang DX, Dong ZR, Li T. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. J Cancer Res Clin Oncol. 2022 Jun 29. doi: 10.1007/s00432-022-04133-8. Epub ahead of print. (Corresponding author, SCI, IF: 4.322).
7.Han CL, Yan YC, Yan LJ, Meng GX, Yang CC, Liu H, Ding ZN, Dong ZR, Hong JG, Chen ZQ, Li T. Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades. J Cancer Res Clin Oncol. 2022 Apr 28. doi: 10.1007/s00432-022-04008-y. Epub ahead of print. (Corresponding author, SCI, IF: 4.322).
8.Ding ZN, Dong ZR,ChenZQ, Hong JG,YanLJ, Li HC, Yao SY, Yan YC, Yang YF, Yang CC,LiT. Viral status and efficacy of immunotherapy in hepatocellular carcinoma: A systematic review with meta-analysis. Front Immunol. doi: 10.3389/fimmu.2021.733530. (Corresponding author, SCI, IF: 8.786)
9.Han-CH, Meng GX, Ding-ZN, Dong ZR, Chen-ZQ, Hong JG, Yan LJ, Liu H, Tian BW, Yang LS, Xue JS,Li T. The Predictive Potential of the baseline C-reactive protein levels for the efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front Immunol,2022.13:827788. (Corresponding author, SCI, IF: 8.786)
10.Xue JS, Ding ZN, Meng GX, Yan LJ, Liu H, Li HC, Yao SY, Tian BW, Dong ZR, Chen ZQ, Hong JG, Wang DX, Li Tao.The prognostic value of natural killer cells and their receptors/ligands in hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol,2022.872353. (Corresponding author, SCI, IF: 8.786).
11.Yan LJ, Yao SY, Li HC, Meng GX, Liu KX, Ding ZN, Hong JG, Chen ZQ, Dong ZR,Li T. Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis. J Clin Transl Hepatol 2022, doi: 10.14218/JCTH.2021.00257. (Corresponding author, SCI, IF: 5.065)
12.Xue JS, Liu H, Meng GX, Ding ZN, Yan LJ, Yao SY, Li HC, Dong ZR, Chen ZQ, Hong JG,Li T. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022;71(7):1633-1644. (Corresponding author, SCI, IF: 6.630)
13.Yang CC, Meng GX, Dong ZR,Li T. Role of Rab GTPases in Hepatocellular Carcinoma.J Hepatocell Carcinoma.2021;8:1389-1397. (Corresponding author, SCI, IF: 5.828)
14.Yan YC, Meng GX, Ding ZN, Liu YF, Chen ZQ, Yan LJ, yang YF, Liu H, Yang CC, Dong ZR, Hong JG,Li T. Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies.J Cancer 2022; 13(1):88-101. (Corresponding author, SCI, IF: 4.478)
15.Liu KX,HongJG, Wu R, Dong ZR, Yang YF, Yan YC, Yang CC,YanLJ, Yao SY, Li HC,ZhiXT,LiT. Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis. Front Oncol 2021. 11:605648. (Corresponding author, SCI, IF: 6.244)
16.Dong ZR, Chen ZQ, Yang XY, Ding ZN, Liu KX, Yan LJ, Meng GX, yang YF, Yan YC, Yao SY, Yang CC, Zhi XT,Li T. RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival.J Cancer 2021; 12(13):3827-3840. (Corresponding author, SCI, IF: 4.478)
17.Yan LJ, Yao SY, Meng GX, Liu KX, Li HC, Ding ZN, Dong ZR, Hong JG, Chen ZQ,Li T. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis. Hepatol Int 2021;15:1413-1420. (Corresponding author, SCI, IF: 9.029)
18.Chen Z, Yu B, Bai J, Li Q, Xu B, Dong Z, Zhi X,Li T.The Impact of Intraoperative Frozen Section on Resection Margin Status and Survival of Patients Underwent Pancreatoduodenectomy for Distal Cholangiocarcinoma. Front. Oncol. 2021,11:650585. (Corresponding author, SCI, IF: 6.244)
19.Ding ZN, Dong ZR, Chen ZQ, Yang YF, Yan LJ, Li HC, Liu KX, Yao CY, Yan YC, Yang CC,Li T.Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis. J Gastroenterol Hepatol.2021,36(6):1487-1496. (Corresponding author, SCI, IF:4.369)
20.Liu H, Yang X-L, Yang X-Y, Dong Z-R, Chen Z-Q, Hong J-G,Li T.The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients with Solid Cancer: A Systematic Review and Meta-Analysis. Front. Oncol. 11:691002. (Corresponding author, SCI, IF: 6.244)
21.Yu B, Zhi X, Li Q, Xu B, Dong Z,Li T, Chen Z. The efficacy and safety of preoperative cholangiography via percutaneous transhepatic gallbladder drainage for difficult laparoscopic cholecystectomy. Surg Endosc.2022, 36:1355–1361 (Corresponding author, SCI, IF:4.584).
22.Xu B, Chen Z, Zhang J, Chang J, Zhao W, Dong Z, Zhi X,Li T.Prognostic Value of Peripheral Whole Blood Cell Counts Derived Indexes in Gallbladder Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol. 2021,11:707742. (Corresponding author, SCI, IF: 6.244)
23.Zhang H, Hong J,Li T. Large low-grade cystic pancreatic neuroendocrine neoplasm. J Hepatobiliary Pancreat Sci. 2020 Oct 14. doi: 10.1002/jhbp.846. Epub ahead of print. (Corresponding author, SCI, IF:7.027)
24.Su P, Hong J,Li T.An Uncommon Lesion of the Liver. Gastroenterology. 2021:7:2258-2260. (Corresponding author, SCI, IF:33.883).
25.Dong ZR, Zhi XT,Li T. A rapidly progressing polycystic liver disease? Gastroenterology 2020;158(1):e9-e11. (Corresponding author, SCI, IF:33.883)
26.Jin B,Du G,Li T. Right upper abdominal distension and discomfort caused by a massive hepatic tumor. Gastroenterology 2017, 153:e24-e26. (Corresponding author, SCI, IF: 33.883)
27.Jiang RD, Zhang ZL,Li T. Abdominal pain caused by spontaneous rupture of a liver tumor. Gastroenterology 2015,149:35-36. (Corresponding author, SCI, IF: 33.883)
28.Li T. An incidentally discovered abdominal mass during physical examination. Gastroenterology 2016, 151:e16-7. (Corresponding author, SCI, IF: 33.883)
29.Xiang TG, Liu GX,Li T. An unusual cause of life-threatening upper gastrointestinal bleeding. Gastroenterology 2016;151:400-2. (Corresponding author, SCI, IF: 33.883)
30.Jiang RD, Zhang ZL,Li T. Calcified Cyst in the Spleen. JAMA Surg 2016, 151:675-6. (Corresponding author, SCI, IF:16.681)
31.Li T, Hao CY, Zhang ZL. Hematochezia caused by a colon disease with unusual presentation. Gastroenterology 2018;154(4):e1-e3 (Corresponding author, SCI, IF: 33.883).
32.Li T, Wang SK, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Fan J. PositiveHBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC. Liver Int 2016,36:284-92（Corresponding author, SCI, IF:8.754）
